🇺🇸 FDA
Patent

US 8791250

Compositions and methods for inhibiting expression of the HAMP gene

granted A61PA61P43/00A61P7/06

Quick answer

US patent 8791250 (Compositions and methods for inhibiting expression of the HAMP gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P43/00, A61P7/06